# StockWatch: Will BMS–2seventy Deal Prove a Win-Win?
## Main Ideas:
– BMS investors are not entirely positive about acquiring 2seventy.
– Uncertainty lingers about the competitiveness of Abecma in the multiple myeloma space.
– Abecma faces strong competition from a blockbuster rival.
– The emergence of a new competitor drug next year adds to the uncertainty.
### Author’s Take:
Investors are cautious about the BMS-2seventy deal as doubts about Abecma’s competition and the upcoming rival drug create a cloud of uncertainty in the multiple myeloma market.
Click here for the original article.